The Economics Of Lowering Cholesterol Among Filipinos

Published May 17, 2013
Manila, Philippines - Heart attack and strokes are among the top causes of death in the Philippines. On the other hand, high cholesterol (dyslipidemia) is one of the important risk factors for cardiovascular diseases like stroke and heart attack. Medications for dyslipidemia presents an additional financial burden to the resource-constrained Filipino population whose health care is obtained mostly through out-of-pocket payments. In the setting of secondary prevention, treatment with 40 mg simvastatin daily was the most cost-effective option compared to the other therapies if the lower-priced generic counterparts were used, while pravastatin 40 mg daily was the most cost-effective alternative if the higher-priced innovator drugs were used. In all sensitivity analyses, gemfibrozil was strongly dominated by the statins. The study “Economic Evaluation of Lipid-Lowering Therapy in the Secondary Prevention Setting in the Philippines” was done in the National Capital Region, Philippines to determine the cost-effectiveness of lipid lowering therapy in the secondary prevention of cardiovascular events in the Philippines. In the base case analysis (primary analysis using the lowest cost in the range of cost estimates, etc.), Simvastatin was the most cost-effective option (best option considering cost and quality and quantity of life, i.e., quality-adjusted life years) compared to Pravastatin, Atorvastatin and Gemfibrozil (medications used for lowering cholesterol). Choosing Pravastatin over Simvastatin, one needs to spend more and would get less, while if Atorvastatin will be used instead of Simvastatin, the additional cost for every quality-adjusted life year would be P121,654. Dr. Tumanan-Mendoza, University of Santo Tomas, Manila, Philippines, states “Simvastatin and Pravastatin are the more cost-effective options compared to Atorvastatin and Gemfibrozil for dyslipidemia for secondary prevention in the Philippines (as of the time of the study).”
Value in Health Regional Issues  (ISSN 2212-1099) is a scientific journal that encourages and enhances the science of pharmacoeconomic/health economic and health outcomes research and its use in health care decisions. The journal is published up to three times a year with one issue focusing on the Asia region, one issue focusing on the Latin America region, and one issue focusing on the Central & Eastern Europe, Western Asia and Africa regions. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

Related Stories

Value in Health Regional Issues Expands Editorial Scope and Reveals Plans to Transition to Gold Open Access Model

Jan 23, 2024

Value in Health Regional Issues, an official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the expansion of its editorial scope and its plan to transition to a gold open access journal.

Empowering Change: Transforming Health Systems in Low- and Middle-Income Countries

Jan 22, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health Regional Issues that highlight innovative approaches to improving health outcomes in low- and middle-income countries through partnerships between health economics researchers and policy makers.

ISPOR’s Value in Health Regional Issues Receives Its First Impact Factor Score

Aug 7, 2023

Value in Health Regional Issues, the regionally focused journal of ISPOR, received its first-ever impact factor score this year. Value in Health, one of the top-ranked journals in the HEOR field, maintained its high ranking on the prestigious list of scholarly journals.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×